The likely causal relationship between low androgen levels and aging, in addition to its association with increased cardiovascular disease, is the hypothesis fueling our scientific expert review.
Las Vegas, NV (PRWEB) July 13, 2011
The August 2011 issue of the Journal of Geriatric Cardiology publishes the global leader in age management medicine’s findings on the link between andropause and cardiovascular disease, announced Cenegenics® Medical Institute. The scientific expert review—entitled “Andropause and the development of cardiovascular disease: More than an epi-phenomenon”—is yet another investigative research collaboration of Cenegenics and Dr. Ernst R. von Schwarz, a professor of medicine at UCLA’s David Geffen School of Medicine.
The cornerstone of their expert review is the coexistence of two phenomena: declining male hormones and the rise of coronary artery disease. Andropause refers to a generalized decline of male hormones, which have been associated with changes such as depression, loss of libido, sexual dysfunction and body composition. Some men may also demonstrate early signs for metabolic de-arrangements—such as metabolic syndrome and vascular dysfunction, i.e. endothelial dysfunction—which may develop into coronary artery disease, heart attacks and stroke.
“Our scientific expert review article goes beyond an epi-phenomenon, which suggests two conditions occurring at the same time, but not related. The likely causal relationship between low androgen levels and aging, in addition to its association with increased cardiovascular disease, is the hypothesis fueling that expert review,” Schwarz said.
According to Schwarz, he has evidenced a vicious cycle in patients who have coronary heart disease with reduced levels of testosterone and other sexual hormones: Aging brings hormonal declines and the development of heart disease—while the heart disease instigates the sexual hormones to decline even more.
“Whether replacement of testosterone in these men would be able to prevent the development or worsening of heart diseases is currently unknown. However, numerous studies on men and women with heart failure showed that when treated with androgen therapy, they experience better functional capacity than those who aren’t undergoing the treatment,” Schwarz said.
Per the collaborative scientific review article, the use of androgen replacement therapy in andropausal men may be clinically indicated, and with the appropriate supervision and follow up may prove to be beneficial with regard to preservation of the integrity of cardiovascular health at higher ages.
Cenegenics' research is done via its nonprofit Cenegenics Education and Research Foundation (CERF). For more information about Cenegenics’ research, medical library dedicated to age management medicine and its highly regarded, CME-accredited Physician Training & Certification in Age Management Medicine, please visit the CERF site.
For more information on Cenegenics, please visit their site, where you can register to read their online Healthy Aging Kit, which includes the informative Guide to Healthy Aging, Executive Summary and media excerpts.
To speak with Cenegenics' Chief Medical Officer and co-author of the scientific expert review, Dr. Robert D. Willix, Jr., please call 702.953.1523.
To schedule an interview, please contact Ann Castro, Cenegenics Director of Media Relations: 702.953.1588.
About Ernst R. von Schwarz, MD, PhD, FESC, FACC, FSCAI
Dr. Ernst R. von Schwarz is board certified in internal medicine by the American Board of Internal Medicine and in cardiology/cardiovascular diseases by the American Board of Internal Medicine. He is a noted professor of medicine at UCLA’s David Geffen School of Medicine. As a clinician and scientist, Schwarz has written more than 100 articles for peer-reviewed publications and has written 10 book chapters on cardiovascular medicine.
Cenegenics® Medical Institute, recognized leading authority in age management medicine, has two centers in Las Vegas, Nevada, as well as centers in Charleston, South Carolina; Boca Raton, Florida; Dallas, Texas; Arlington, Texas; Atlanta, Georgia; Chicago, Illinois; Beverly Hills, California; Philadelphia, Pennsylvania; Washington, DC; New York City, NY; Tulsa, OK; Jacksonville, FL; Atlantic City, NJ; Houston,TX; Denver, CO. Additional centers are scheduled to open in other major metropolitan areas in the near future. With an established presence in the medical community, Cenegenics uses a proactive approach based on solid science and comprehensive evaluation. Their established protocols have been recognized as the next generation of medical science, capturing global attention. Cenegenics offers CME-accredited physician training and certification opportunities in age management medicine via the nonprofit Cenegenics Education and Research Foundation (CERF). Headquartered in Las Vegas, Cenegenics serves more than 20,000 patients worldwide—2,000 are physicians and their families.